Evidence map›Paper›PMID 31587995›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2019

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.

Stephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, Paul B Rosenberg, Bruce G Pollock, Davangere P Devanand, Jacobo Mintzer, Tarek K Rajji, Zahinoor Ismail, Lon S Schneider and 6 more

Registry-linked trialOpen access · greenAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03108846 (Escitalopram for Agitation in Alzheimer's Disease), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03108846 phase3active not recruitingnot on this map

Escitalopram for Agitation in Alzheimer's Disease

TypeinterventionalSponsorJHSPH Center for Clinical TrialsRan2018 to 2025Enrolled187ConditionsDementiaArmsEscitalopram, Placebo
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Treatment of agitation in dementia - a systematic review.International journal of emergency medicine · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Alzheimer's disease drug development pipeline: 2020.Alzheimer's & dementia (New York, N. Y.) · 2020
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Stephan EhrhardtDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sehrhar6@jhu.edu.
Anton P PorsteinssonDepartment of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Cynthia A MunroDivision of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Paul B RosenbergDivision of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Bruce G PollockCampbell Family Research Institute and Division of Adult Neurodevelopment and Geriatric Psychiatry, CAMH, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Davangere P DevanandDivision of Geriatric Psychiatry, New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Jacobo MintzerRoper St. Francis Research and Innovation Center, Charleston, SC, USA; Medical University of South Carolina, College of Health Professionals and Ralph H Johnson VA Medical Center, Charleston, SC, USA.
Tarek K RajjiCampbell Family Research Institute and Division of Adult Neurodevelopment and Geriatric Psychiatry, CAMH, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Zahinoor IsmailDepartment of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.
Lon S SchneiderDepartments of Psychiatry and the Behavioral Sciences and Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA; Department of Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA.
Sheriza N BakshDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lea T DryeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Dimitri AvramopoulosDepartment of Psychiatry and Behavioral Sciences, Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David M ShadeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Constantine G LyketsosDivision of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
S-CitAD Research Group
Johns Hopkins University · USJohns Hopkins Bayview Medical Center · USColumbia University · USJohns Hopkins Medicine · USNeuroDevelopment Center · USOntario Brain Institute · CARalph H. Johnson VA Medical Center · USUniversity of Rochester · USUniversity of Southern California · USUniversity of Toronto · CA

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
The University of Rochester's Clinical and Translational Science InstituteUL1TR002001 · NCATS · UNIVERSITY OF ROCHESTER · PI WILSON, KAREN M., ZAND, MARTIN S · 2016 to 2024
$34.6M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
The Coronavirus Pandemic, Caregiver Distress, And Neuropsychiatric Symptoms In Individuals With Alzheimer's DiseaseR01AG052510 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G, PORSTEINSSON, ANTON P · 2016 to 2022
$16.8M
Statistical methods for characterizing patients who highly-benefit from treatments and programs in Alzheimers, HIV, and other heterogeneous diseasesR01AI140854 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FRANGAKIS, CONSTANTINE E · 2018 to 2021
$1.8M
NCATS NIH HHS UL1 TR002001NIAID NIH HHS R01 AI140854NIA NIH HHS P30 AG066507NIA NIH HHS P50 AG005142NIA NIH HHS R01 AG052510
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD.

methodsS-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). DISCUSSION: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).

Indexed as

AgedAged, 80 and overAlzheimer DiseaseCitalopramDouble-Blind MethodFemaleHumansMaleMulticenter Studies as TopicPragmatic Clinical Trials as TopicPsychiatric Status Rating ScalesPsychomotor AgitationRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsCitalopramSelective Serotonin Reuptake InhibitorsAgitationAlzheimer dementiaEscitalopramNeuropsychiatric symptomsPsychosocial interventionRandomized trial

Identifiers

PMID31587995
PMCPMC6889953
OpenAlexW2978577535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.